Key terms
About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VRTX news
Yesterday
7:31pm ET
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Apr 18
6:45pm ET
Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition
Apr 18
12:15pm ET
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Apr 18
8:30am ET
Vertex Pharmaceuticals announces advancements in suzetrigine pain program
Apr 15
2:05pm ET
Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
Apr 15
7:40am ET
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 12
10:55am ET
Vertex Pharmaceuticals’ Hold Rating: Balancing Cystic Fibrosis Success with Uncertain Growth from New Acquisition
Apr 12
1:41am ET
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Apr 12
1:40am ET
Buy Rating Affirmed: Vertex Pharmaceuticals’ Strategic Acquisition and Market Positioning Promise Growth
Apr 12
1:37am ET
Analyst Maintains ‘Sell’ Rating on Vertex Pharmaceuticals Amid Skepticism Over Alpine Acquisition and Early-Stage Data
Apr 11
7:48pm ET
Alpine Immune Sciences downgraded to Market Perform from Outperform at Leerink
Apr 11
10:49am ET
Analyst thinks this drugmaker could be next after Alpine’s $4.9B acquisition
Apr 11
9:40am ET
DoorDash upgraded, Airbnb downgraded: Wall Street’s top analyst calls
Apr 11
8:43am ET
Vertex Pharmaceuticals price target raised to $462 from $457 at H.C. Wainwright
Apr 11
6:34am ET
Evercore expects Vera Therapeutics to trade up on Alpine acquisition news
Apr 11
6:26am ET
Vertex Pharmaceuticals upgraded to Outperform from In Line at Evercore ISI
Apr 11
6:23am ET
Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
Apr 11
5:10am ET
Alpine Immune downgraded to Sector Perform from Outperform at RBC Capital
Apr 10
4:02pm ET
Vertex to acquire Alpine Immune Sciences for $65 per share
Apr 08
10:30pm ET
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
Apr 08
10:07am ET
RBC says pain opinion leader ‘notably negative’ on Vertex’s VX-548
Apr 03
9:25am ET
Truist pharmaceuticals analyst holds an analyst/industry conference call
Apr 03
4:55am ET
Truist pharmaceuticals analyst holds an analyst/industry conference call
Apr 02
7:25am ET
Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Apr 02
7:20am ET
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
Apr 02
5:31am ET
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Vertex Pharmaceuticals (VRTX) and Veeva Systems (VEEV)
Apr 01
11:04am ET
Vertex announces acceptance of NDS for exagamglogene autotemcel
Apr 01
8:10am ET
Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
Mar 31
10:29pm ET
Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
Mar 28
1:29pm ET
Truist pharmaceuticals analyst holds an analyst/industry conference call
No recent press releases are available for VRTX
VRTX Financials
Key terms
Ad Feedback
VRTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VRTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range